OSUR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OS

Mkt Cap

$250.0M

Volume

260.00K

Next Earnings

November 4th

Loading chart

OS

OSUROraSure Technologies Inc

OSUR

Pay with—

Available Balance0.00

OS

Mkt Cap

$249.0M

Volume

260.00K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Is Co-Diagnostics National Security’s Next Diagnostic Pick?Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.Investing.com · May 28, 2026

OraSure (OSUR) Q1 2026 Earnings TranscriptOraSure Technologies reported Q1 2026 revenue of $27.9 million (4% sequential growth) with diagnostics revenue up 12% sequentially. The company achieved gross margin expansion to 42.3% GAAP and 43.4% non-GAAP through manufacturing insourcing. Despite operating losses of $23.3 million GAAP, the company maintains $177 million in cash with no debt. Key catalysts include two FDA submissions for CT/G rapid self-test and COLI P urine collection device expected for midyear clearance with second-half revenue ramp. Management expects return to breakeven operating cash flow by 2027.The Motley Fool · May 6, 2026

OraSure Technologies Appoints John D. Bertrand to its Board of DirectorsOraSure Technologies announced the appointment of John D. Bertrand, a healthcare technology executive with AI-enabled diagnostics expertise, to its Board of Directors. The company will seek shareholder approval to declassify its Board at the 2026 Annual Meeting. Following constructive engagement, OraSure entered into a Cooperation Agreement with activist investor Altai Capital Management, which will withdraw its director nominations in exchange for regular strategic discussions with the company's Board and management.GlobeNewswire Inc. · Apr 17, 2026

Drug Screening Market Trends 2026–2031: Chromatography and Mass Spectrometry Held a 44.77% Share in 2025 Amid Growing Demand for Advanced Testing, Reports Mordor IntelligenceThe global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.GlobeNewswire Inc. · Apr 3, 2026

OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - Privacy, Digital Access, and Rapid Results Accelerate AdoptionA comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.GlobeNewswire Inc. · Feb 3, 2026

OraSure Technologies Confirms Receipt of Director Nominations from Altai CapitalOraSure Technologies confirmed that activist investor Altai Capital has nominated two candidates, including founder Rishi Bajaj, for election to the company's Board of Directors at the 2026 Annual Meeting. The Board previously interviewed Bajaj but appointed an alternative candidate instead. OraSure highlighted its recent board refreshment with seven departures and three new independent directors added since 2022, including Steven K. Boyd in October 2025 and John P. Kenny as new Chair.GlobeNewswire Inc. · Jan 15, 2026

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA ReviewOraSure Technologies announced the submission of two FDA applications at the end of 2025: one for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) that delivers results in approximately 30 minutes, and another for its Colli-Pee at-home urine collection device for STI testing. The CT/NG test addresses a market opportunity exceeding $1.5 billion, with the company positioning these submissions as key milestones in its strategy to decentralize diagnostics and improve healthcare accessibility.GlobeNewswire Inc. · Jan 5, 2026

Global At-Home Testing Market to Reach USD 11,877.8 Million by 2035 with a CAGR of 4.8%, Driven by Rising Consumer Demand for Self-Diagnostic Tools | Future Market Insights, Inc.The global at-home testing market is expected to grow from $7.8 billion in 2025 to $11.9 billion by 2035, driven by increasing consumer demand for self-diagnostic tools. Key factors include rising healthcare spending, growing awareness of preventive healthcare, and technological advancements in diagnostic tools.GlobeNewswire Inc. · Jan 17, 2025

OraSure Technologies Acquires Sherlock BiosciencesOraSure Technologies has acquired Sherlock Biosciences, a global health company that develops next-generation diagnostic tests. The acquisition expands OraSure's pipeline with Sherlock's molecular diagnostics platform, which can provide rapid and accurate results for sexually transmitted infections.Benzinga · Dec 19, 2024

Microbiome Diagnostics Market to hit USD 429.2 million by 2032, says Global Market Insights Inc.The microbiome diagnostics industry is projected to grow at a CAGR of 13.4% from 2024 to 2032, driven by the rising demand for personalized medicine. Advancements in sequencing technologies and collaborations between research organizations are expected to drive the market.GlobeNewswire Inc. · Oct 29, 2024

to start trading

OS

OSUROraSure Technologies Inc

OSUR

Pay with—

Available Balance0.00

Your PositionYou don't own any OSUR yet.

Related Tickers

Earnings